Key result
Candesartan improved patient perception of symptoms compared to placebo, with more patients reporting improvement (37.7% vs 33.5%) and fewer reporting deterioration (10.8% vs 12.0%; p=0.017).
Why the study?
Does candesartan improve patient perception of symptoms in patients with symptomatic chronic heart failure?
Population
2,498 patients with symptomatic chronic heart failure (CHF) in North America
Comparison
Candesartan added to extensive background therapy vs Placebo added to extensive background therapy
Design
RCT, randomised
Follow-up
up to final visit (assessments at 6, 14, and 26 months)
Authors
Loading...
Candesartan improves symptom perception in chronic HF; extends RCT evidence to patient-reported outcomes.
RCT (n=2,498)
randomized
Yes
Does candesartan improve patient perception of symptoms in patients with symptomatic chronic heart failure?
Absolute Event Rate: 37.7% vs 33.5%
p-value: p=0.017
Candesartan significantly improves patient-reported symptom perception compared to placebo in patients with chronic heart failure.
O’Meara et al. (2005) conducted an RCT in chronic heart failure (CHF) (n=2,498). candesartan vs. placebo was evaluated on McMaster Overall treatment evaluation (OTE) improvement (LVCF analysis) (p=0.017). Candesartan improved patient perception of symptoms compared to placebo, with more patients reporting improvement (37.7% vs 33.5%) and fewer reporting deterioration (10.8% vs 12.0%; p=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: